Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Our Patients
Focusing on the unmet medical needs of patients with rare disorders and their families
Our Company
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Latest News
05.05
Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome
Read More04.29
Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
Read More04.15
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
Read More